Ibudilast for the Treatment of Alcohol Use Disorder
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study is a double-blind, placebo-controlled randomized clinical trial of IBUD (50mg BID)
for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week
medication treatment period and 5 in-person visits over 16 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, Los Angeles
Collaborators:
MediciNova National Institute on Alcohol Abuse and Alcoholism (NIAAA)